Arthritis & Rheumatism

Volume 37, Issue 1 p. 147

Letter

Full Access

Reply

P. P. Sfikakis MD, 

P. P. Sfikakis MD

Athens University Medical School Athens, Greece

Search for more papers by this author

P. Panayotidis MD, 

P. Panayotidis MD

Royal Free Hospital London, UK

Search for more papers by this author

P. P. Sfikakis MD, 

P. P. Sfikakis MD

Athens University Medical School Athens, Greece

Search for more papers by this author

P. Panayotidis MD, 

P. Panayotidis MD

Royal Free Hospital London, UK

Search for more papers by this author

First published: January 1994

https://doi.org/10.1002/art.1780370124

Citations: 1

No abstract is available for this article.

References

• 1 Harth M, Cousin K, McCain GA: Sodium aurothiomalate inhibits T cell responses to interleukin-2. Immunopharmacol Immunotoxicol 10: 141–156, 1988
  10.3109/08923978809014329

  CAS PubMed Web of Science® Google Scholar
• 2 Wolf RE, Hall VC: Inhibition of in vitro proliferation response of cultured T lymphocytes to interleukin-2 by gold sodium thiomalate. Arthritis Rheum 31: 176–181, 1988
  10.1002/art.1780310204

  CAS PubMed Web of Science® Google Scholar
• 3 Gottlieb NL: Comparative pharmacokinetics of parenteral and oral gold compounds. J Rheumatol 9 (suppl 8): 99–109, 1982
  Web of Science® Google Scholar
• 4 Blodgett RC, Heuer MA, Pietrusko RG: Auranofin: a unique oral chrysotherapeutic agent. Semin Arthritis Rheum 13: 255–273, 1984
  10.1016/0049-0172(84)90029-5

  CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume37, Issue1

January 1994

Page 147

• References

• Related

• Information

Close Figure Viewer

Previous FigureNext Figure

Caption

Download PDF